Wang JS, Xia PF, Ma MN, Li Y, Geng TT, Zhang YB, et al. Trends in the Prevalence of Metabolically Healthy Obesity Among US Adults, 1999–2018. JAMA Netw Open. 2023;6(3): e232145. https://doi.org/10.1001/jamanetworkopen.2023.2145.
Article PubMed PubMed Central Google Scholar
Chitaley K, Kupelian V, Subak L, Wessells H. Diabetes, obesity and erectile dysfunction: field overview and research priorities. J Urol. 2009;182(6 Suppl):S45-50. https://doi.org/10.1016/j.juro.2009.07.089.
Article PubMed PubMed Central Google Scholar
Akdemir AO, Karabakan M, Aktas BK, Bozkurt A, Ozgur EG, Akdogan N, et al. Visceral adiposity index is useful for evaluating obesity effect on erectile dysfunction. Andrologia. 2019;51(6): e13282. https://doi.org/10.1111/and.13282.
Article CAS PubMed Google Scholar
Surgery TASfMaB. Who is a Candidate for Bariatric Surgery? https://asmbs.org/patients/who-is-a-candidate-for-bariatric-surgery: ASMBS; 2023.
Minambres I, Sarda H, Urgell E, Genua I, Ramos A, Fernandez-Ananin S, et al. Obesity Surgery Improves Hypogonadism and Sexual Function in Men without Effects in Sperm Quality. J Clin Med. 2022;11(17):5126. https://doi.org/10.3390/jcm11175126.
Chen G, Sun L, Jiang S, Chen X, Zhu J, Zhao X, et al. Effects of bariatric surgery on testosterone level and sexual function in men with obesity: A retrospective study. Front Endocrinol (Lausanne). 2022;13:1036243. https://doi.org/10.3389/fendo.2022.1036243.
El-Tholoth HS, Bedaiwi AK, Binjawhar A, Almulhem AA, Bedaiwi KK, Alshurafa H, et al. Male sexual function after weight-loss surgeries in a group of Saudi population. Urol Ann. 2021;13(2):125–9. https://doi.org/10.4103/UA.UA_144_19.
Article PubMed PubMed Central Google Scholar
Machado FP, Rhoden EL, Pioner SR, Halmenschlager G, de Souza LVB, Lisot BC, et al. Weight Loss Through Bariatric Surgery in Men Presents Beneficial Effects on Sexual Function, Symptoms of Testosterone Deficiency, and Hormonal Profile. Sex Med. 2021;9(4): 100400. https://doi.org/10.1016/j.esxm.2021.100400.
Article PubMed PubMed Central Google Scholar
Li H, Xu W, Wang T, Wang S, Liu J, Jiang H. Effect of weight loss on erectile function in men with overweight or obesity: A meta-analysis of randomised controlled trials. Andrologia. 2022;54(1): e14250. https://doi.org/10.1111/and.14250.
Mora M, Aranda GB, de Hollanda A, Flores L, Puig-Domingo M, Vidal J. Weight loss is a major contributor to improved sexual function after bariatric surgery. Surg Endosc. 2013;27(9):3197–204. https://doi.org/10.1007/s00464-013-2890-y.
Fahmy A, Abdeldaiem H, Abdelsattar M, Aboyoussif T, Assem A, Zahran A, et al. Impact of Bariatric Surgery on Sexual Dysfunction in Obese Men. Sex Med. 2021;9(2): 100322. https://doi.org/10.1016/j.esxm.2021.100322.
Article PubMed PubMed Central Google Scholar
Nimbi FM, Virginia C, Cinzia DM, Michela DT, Gianfranco S, Emanuela P. The relation between sexuality and obesity: the role of psychological factors in a sample of obese men undergoing bariatric surgery. Int J Impot Res. 2022;34(2):203–14. https://doi.org/10.1038/s41443-020-00388-2.
Wang CM, Wu BR, Xiang P, Xiao J, Hu XC. Management of male erectile dysfunction: From the past to the future. Front Endocrinol (Lausanne). 2023;14:1148834. https://doi.org/10.3389/fendo.2023.1148834.
Mykoniatis I, Pyrgidis N, Sokolakis I, Ouranidis A, Sountoulides P, Haidich AB, et al. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(2): e2036337. https://doi.org/10.1001/jamanetworkopen.2020.36337.
Article PubMed PubMed Central Google Scholar
Moncada I, Martinez-Salamanca J, Ruiz-Castane E, Romero J. Combination therapy for erectile dysfunction involving a PDE5 inhibitor and alprostadil. Int J Impot Res. 2018;30(5):203–8. https://doi.org/10.1038/s41443-018-0046-2.
Article CAS PubMed Google Scholar
Dahan A, Beig A, Lindley D, Miller JM. The solubility-permeability interplay and oral drug formulation design: Two heads are better than one. Adv Drug Deliv Rev. 2016;101:99–107. https://doi.org/10.1016/j.addr.2016.04.018.
Article CAS PubMed Google Scholar
Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42(6):620–43. https://doi.org/10.1177/00970002042006005.
Article CAS PubMed Google Scholar
Dvorackova E, Pilkova A, Matoulek M, Slanar O, Hartinger JM. Bioavailability of Orally Administered Drugs After Bariatric Surgery. Curr Obes Rep. 2024;13(1):141–53. https://doi.org/10.1007/s13679-023-00548-7.
Konstantinidou SK, Argyrakopoulou G, Dalamaga M, Kokkinos A. The Effects of Bariatric Surgery on Pharmacokinetics of Drugs: a Review of Current Evidence. Curr Nutr Rep. 2023;12(4):695–708. https://doi.org/10.1007/s13668-023-00498-5.
Article PubMed PubMed Central Google Scholar
Porat D, Vaynshtein J, Gibori R, Avramoff O, Shaked G, Dukhno O, et al. Stomach pH before vs. after different bariatric surgery procedures: Clinical implications for drug delivery. Eur J Pharm Biopharm. 2021;160:152–7. https://doi.org/10.1016/j.ejpb.2021.01.016.
Steenackers N, Vanuytsel T, Augustijns P, Tack J, Mertens A, Lannoo M, et al. Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass. Lancet Gastroenterol Hepatol. 2021;6(3):225–37. https://doi.org/10.1016/S2468-1253(20)30302-2.
Azran C, Wolk O, Zur M, Fine-Shamir N, Shaked G, Czeiger D, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev. 2016;17(11):1050–66. https://doi.org/10.1111/obr.12434.
Porat D, Dahan A. Medication Management after Bariatric Surgery: Providing Optimal Patient Care. J Clin Med. 2020;9(5):1511. https://doi.org/10.3390/jcm9051511.
Article PubMed PubMed Central Google Scholar
Porat D, Azran C, Kais H, Dahan A. Managing the Unpredictable: Mechanistic Analysis and Clinical Recommendations for Lamotrigine Treatment after Bariatric Surgery. J Clin Med. 2021;10(23):5627. https://doi.org/10.3390/jcm10235627.
Article CAS PubMed PubMed Central Google Scholar
Azran C, Porat D, Fine-Shamir N, Hanhan N, Dahan A. Oral levothyroxine therapy postbariatric surgery: Biopharmaceutical aspects and clinical effects. Surg Obes Relat Dis. 2019;15(2):333–41. https://doi.org/10.1016/j.soard.2019.01.001.
Zucchi A, Costantini E, Scroppo FI, Silvani M, Kopa Z, Illiano E, et al. The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue. Andrology. 2019;7(6):804–17. https://doi.org/10.1111/andr.12683.
Article CAS PubMed PubMed Central Google Scholar
Wlodarski K, Sawicki W, Haber K, Knapik J, Wojnarowska Z, Paluch M, et al. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil. Eur J Pharm Biopharm. 2015;94:106–15. https://doi.org/10.1016/j.ejpb.2015.04.031.
Article CAS PubMed Google Scholar
Porat D, Dukhno O, Cvijic S, Dahan A. The Complexity of Bariatric Patient's Pharmacotherapy: Sildenafil Biopharmaceutics and Pharmacokinetics before vs. after Gastric Sleeve/Bypass. Pharmaceutics. 2023;15(12). https://doi.org/10.3390/pharmaceutics15122795.
Beig A, Miller JM, Dahan A. The interaction of nifedipine with selected cyclodextrins and the subsequent solubility-permeability trade-off. Eur J Pharm Biopharm. 2013;85(3 Pt B):1293–9. https://doi.org/10.1016/j.ejpb.2013.05.018.
Article CAS PubMed Google Scholar
Beig A, Agbaria R, Dahan A. The use of captisol (SBE7-beta-CD) in oral solubility-enabling formulations: Comparison to HPbetaCD and the solubility-permeability interplay. Eur J Pharm Sci. 2015;77:73–8. https://doi.org/10.1016/j.ejps.2015.05.024.
Article CAS PubMed Google Scholar
Porat D, Dukhno O, Vainer E, Cvijic S, Dahan A. Antiallergic Treatment of Bariatric Patients: Potentially Hampered Solubility/Dissolution and Bioavailability of Loratadine, but Not Desloratadine. Post-Bariatric Surgery Mol Pharm. 2022;19(8):2922–36. https://doi.org/10.1021/acs.molpharmaceut.2c00292.
留言 (0)